Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma in Early High-Risk COVID-19
NCT04589949Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Erasmus MC. Primary endpoint: Highest disease status at 28 days. Started Oct 2020; status: terminated.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04589949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589949.